Evidence map›Paper›PMID 33396968›Full record

ArticleInternational journal of molecular sciences2020

A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells.

Ilya Nifant'ev, Andrei Siniavin, Eduard Karamov, Maxim Kosarev, Sergey Kovalchuk, Ali Turgiev, Sergey Nametkin, Vladimir Bagrov, Alexander Tavtorkin, Pavel Ivchenko

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Sumac Polyphenols as Pan-Herpesvirus Inhibitors.International journal of molecular sciences · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ilya Nifant'evChemistry Department, M.V. Lomonosov Moscow State University, 1-3 Leninskie Gory, 119991 Moscow, Russia.ORCID 0000-0001-9151-1890
Andrei SiniavinN.F. Gamaleya National Research Center for Epidemiology and Microbiology MHRF, 18 Gamaleya Str., 123098 Moscow, Russia.ORCID 0000-0001-7576-2059
Eduard KaramovN.F. Gamaleya National Research Center for Epidemiology and Microbiology MHRF, 18 Gamaleya Str., 123098 Moscow, Russia.
Maxim KosarevChemistry Department, M.V. Lomonosov Moscow State University, 1-3 Leninskie Gory, 119991 Moscow, Russia.
Sergey KovalchukShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Ali TurgievN.F. Gamaleya National Research Center for Epidemiology and Microbiology MHRF, 18 Gamaleya Str., 123098 Moscow, Russia.
Sergey NametkinChemistry Department, M.V. Lomonosov Moscow State University, 1-3 Leninskie Gory, 119991 Moscow, Russia.
Vladimir BagrovChemistry Department, M.V. Lomonosov Moscow State University, 1-3 Leninskie Gory, 119991 Moscow, Russia.
Alexander TavtorkinA.V. Topchiev Institute of Petrochemical Synthesis RAS, 29 Leninsky Pr., 119991 Moscow, Russia.
Pavel IvchenkoChemistry Department, M.V. Lomonosov Moscow State University, 1-3 Leninskie Gory, 119991 Moscow, Russia.ORCID 0000-0002-0181-5952
Lomonosov Moscow State University · RUGamalei Institute of Epidemiology and Microbiology · RUA.V. Topchiev Institute of Petrochemical Synthesis · RUInstitute of Bioorganic Chemistry · RUNational Research University Higher School of Economics · RU

Funding

Russian Science Foundation 16-13-10344
6 · The paper itself

Abstract

Despite the world's combined efforts, human immunodeficiency virus (HIV), the causative agent of AIDS, remains one of the world's most serious public health challenges. High genetic variability of HIV complicates the development of anti-HIV vaccine, and there is an actual clinical need for increasing the efficiency of anti-HIV drugs in terms of targeted delivery and controlled release. Tenofovir (TFV), a nucleotide-analog reverse transcriptase inhibitor, has gained wide acceptance as a drug for pre-exposure prophylaxis or treatment of HIV infection. In our study, we explored the potential of tenofovir disoproxil (TFD) adducts with block copolymers of poly(ethylene glycol) monomethyl ether and poly(ethylene phosphoric acid) (mPEG-

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsHumansPhosphoric AcidsPolyethylenePolymersPrecursor Cell Lymphoblastic Leukemia-LymphomaTenofovirTumor Cells, CulturedAnti-HIV Agentsphosphoric acidPhosphoric AcidsPolyethylenePolymersTenofovirAIDScARTcontrolled releaseHIVinjectable formulationslong-acting drugspolyphosphoesterspoly(phosphoric acid)PrEPring-opening polymerizationtenofovir

Identifiers

PMID33396968
PMCPMC7795142
OpenAlexW3113926822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.